5/30
08:06 am
dtil
Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Medium
Report
Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
5/30
07:24 am
dtil
Precision BioSciences to Participate in Upcoming June Investor Conferences [Yahoo! Finance]
High
Report
Precision BioSciences to Participate in Upcoming June Investor Conferences [Yahoo! Finance]
5/30
07:00 am
dtil
Precision BioSciences to Participate in Upcoming June Investor Conferences
High
Report
Precision BioSciences to Participate in Upcoming June Investor Conferences
5/29
12:15 pm
dtil
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect? [Yahoo! Finance]
5/17
07:06 am
dtil
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
5/17
07:00 am
dtil
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
5/16
02:13 pm
dtil
Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
5/13
07:12 am
dtil
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Neutral
Report
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/13
07:00 am
dtil
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
5/8
08:29 am
dtil
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement [Yahoo! Finance]
5/8
08:15 am
dtil
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
High
Report
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
5/7
04:30 pm
dtil
Precision BioSciences to Report First Quarter Results on May 13, 2024
Medium
Report
Precision BioSciences to Report First Quarter Results on May 13, 2024
5/7
08:49 am
dtil
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
5/7
08:37 am
dtil
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
High
Report
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
5/7
08:30 am
dtil
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Medium
Report
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
5/7
08:00 am
dtil
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Medium
Report
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
5/1
07:25 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 [Yahoo! Finance]
5/1
07:05 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Low
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
4/30
07:15 am
dtil
Precision BioSciences, Inc. (NASDAQ: DTIL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
Precision BioSciences, Inc. (NASDAQ: DTIL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
4/16
04:29 pm
dtil
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics [Yahoo! Finance]
4/16
04:15 pm
dtil
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Medium
Report
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/11
11:41 am
dtil
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
Medium
Report
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
4/4
11:13 am
dtil
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. [Yahoo! Finance]
Low
Report
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. [Yahoo! Finance]
4/4
11:00 am
dtil
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Medium
Report
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
4/2
12:02 pm
dtil
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know [Yahoo! Finance]